LSP Dementia Fund closes at 260m
EQT Life Sciences has closed the LSP Dementia Fund at approximately 260m, 2.6-fold over the target fund size of 100m.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 801 entries already.
Entries by Thomas Gabrielczyk
Secarna Pharmaceuticals partners with SciNeuro Pharmaceuticals
/in News/by Thomas GabrielczykAntisense drug developer Secarna Pharmaceuticals and CNS expert SciNeuro Pharmaceuticals have inked an R&D and licence option contract for CNS diseases.
Hot of the press: new issue of BIOTECH Insight
/in News/by Thomas GabrielczykThe latest issue of BIOTECH Insight newsletter of Deutsche Börse in collaboration with BIOCOM AG is out, covering hot topics of the German biotech sector.
Algal enzyme synthesizes gasoline building blocks
/in News/by Thomas GabrielczykAn algal photoenzyme that synthesizes medium-chain hydrocarbons the building blocks of gasoline is set to boost industrial-scale production of biofuels.
Macomics licences macrophage modulator to Ono
/in News/by Thomas GabrielczykEdinburgh-based immuno-oncology expert Macomics Ltd has partnered with Ono Pharmaceutical to develop a macrophage-targeting antibody targetting cancer.
mbiomics GmbH cashes in 13m in Series A financing
/in News/by Thomas GabrielczykMunich-based microbiome therapeutics specialist mbiomics GmbH has raised 13m in the first closing of Series A round led by MIG Capital.
500 experts at the 7th AMR Conference in Basel
/in News/by Thomas GabrielczykHow to stop hard-to-diagnose, treatment-resistant microbial pathogens was discussed by experts from 13 countries at the 7th AMR Conference in Basel.
Vitestro raises 12m in Series A financing
/in News/by Thomas GabrielczykWith assets of 12m through a Series A financing, Dutch Vitestro NV aims to bring the world’s first autonomous blood drawing device to the market.
European VCs join US$105m financing of US Mediar Thx
/in News/by Thomas GabrielczykMediar Therapeutics (Cambridge, MA, USA), a company developing a portfolio of first-in-class therapies to treat fibrosis, announces a US$105m financing including a US$85m Series A co-led by Novartis Venture Fund and Sofinnova Partners (France). The round is further joined by Pfizer Ventures, Mission BioCapital, Bristol-Myers Squibb, Eli Lilly, Ono Venture Investment, Mass General Brigham Ventures […]
Iktos SA raises 15.5m in Series A financing
/in News/by Thomas GabrielczykParis-based AI-inspired drug discovery specialist Iktos SA has closed a 15.5m financing to expand its platform and kick-start the new CRO Iktos Robotics.